Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
about
Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trialsMitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug developmentAlpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potentialMetabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom controlPathways in the diagnosis and management of diabetic polyneuropathyRanirestat for the management of diabetic sensorimotor polyneuropathyRepurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trialSafety and efficacy of an add-on therapy with curcumin phytosome and piperine and/or lipoic acid in subjects with a diagnosis of peripheral neuropathy treated with dexibuprofenDietary lipoic acid-dependent changes in the activity and mRNA levels of hepatic lipogenic enzymes in ratsTargeting neuroprotection as an alternative approach to preventing and treating neuropathic painDiabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function.Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway.Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin.Treatment of diabetic sensory polyneuropathy.A 41-year-old man with polyarthritis and severe autonomic neuropathy.Painful diabetic neuropathy: advantage of novel drugs over old drugs?Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities.Therapeutic interventions and oxidative stress in diabetesDiabetic neuropathy part 1: overview and symmetric phenotypesObesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy.The Association between Serum GGT Concentration and Diabetic Peripheral Polyneuropathy in Type 2 Diabetic Patients.Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases.Prevalence and correlates of diabetic peripheral neuropathy in a Saudi Arabic population: a cross-sectional study.Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study.Systematic review of treatments for diabetic peripheral neuropathy.Nutritional supplements and their effect on glucose control.Proficiency of nerve conduction using standard methods and reference values (Cl. NPhys Trial 4)Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy.Effects of aspirin & simvastatin and aspirin, simvastatin, & lipoic acid on heme oxygenase-1 in healthy human subjects.Alpha lipoic acid attenuates radiation-induced thyroid injury in rats.Evaluation of PMI-5011, an ethanolic extract of Artemisia dracunculus L., on peripheral neuropathy in streptozotocin-diabetic mice.Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy.Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series.Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms.Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials.Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury.Role of Drp1, a key mitochondrial fission protein, in neuropathic pain.Update on the management of diabetic polyneuropathies.Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.(R)-(+)-α-lipoic acid protected NG108-15 cells against H₂O₂-induced cell death through PI3K-Akt/GSK-3β pathway and suppression of NF-κβ-cytokines.
P2860
Q21285063-CF453814-1FCE-4CA9-BB4E-18250F8E1C12Q22241837-EA652F5E-C035-40E1-B039-307B2DF3F17DQ24658099-FB4A5BF2-8DEB-44FD-A78A-4ABE8F671292Q26852079-FCF41CF7-C3AE-4A06-B312-DE110A41E53BQ28082465-3EB23257-C871-4F1D-A77F-109CEA194E72Q28241270-05C8867E-011D-4F5B-8CBA-3EC625775071Q28304712-DFA26982-5533-47B6-8B92-2B53F6C3536BQ28385294-0685D75A-3904-4051-AFD8-C766856C22FBQ28569638-AF1D978F-1865-4905-BB3E-ED1D03E46561Q28820780-FCBA753F-DD36-48EF-93BD-2930A269CA4CQ30239828-ED523494-59CA-4046-B182-B634E0EFA8F4Q30432705-558671FA-FE9C-42F9-8318-6C7B75000DC0Q30537158-6C1FE524-50A8-43A2-86D1-F8CAB5754E8CQ33393882-91B0ECD2-ED97-4B07-BE24-E1CC9A60F3B6Q33408182-43C37206-A56D-4222-874B-ABB23A5CA551Q33610824-E3C460D4-79E8-4867-BC4B-AC99F6A824B8Q33668501-545E6D49-3E2D-4E61-88FF-AB45F78E7223Q33870395-4513C8F2-39B8-4518-A46F-449EDEAA78BBQ33878023-8575FBC5-FF5A-4437-B1B9-FD7A5523A7BAQ33887571-900DD38B-695F-4C86-A085-919CC0F3442CQ33904484-5D8B8C10-C9BD-439E-804E-1EACF9444E04Q34012029-65D3564F-E2CC-4C83-A97D-237A946BBFC0Q34128919-01DE6D92-248D-4801-8B56-19629BDD5B6CQ34156106-84639C87-4840-4A9F-8993-7A7EEF58B900Q34161497-5C68024A-F5FD-4A05-BB6C-841E19D7DE70Q34162991-5FC0F180-9493-46D5-BC2F-192C0FF170ECQ34214542-3E953DB2-C700-4829-9E7B-55EE975AADCBQ34218901-3EC476E3-2983-4BED-812A-E388E306FA54Q34255336-5D2430B2-C416-4E7B-B18D-7D8612289168Q34525368-76AD67E9-9999-4A1C-B00C-500A117D59F4Q34603050-761A9870-BBAC-4912-A5C9-FF358E3A44E5Q34631169-94F07119-E04D-4BFE-81A9-0975E7CEABB3Q34645584-CE54BF91-4F24-4B84-8D22-97579585591AQ34646991-71B53D56-A960-41B7-8800-6FDF4FA72540Q34685307-CD3E1F07-820C-41CC-A1D1-6AAC949EE7A4Q34730353-E5418EA2-8351-48FE-A4F0-5DB199A8EBB6Q35168122-86CEDD88-83D0-41C3-9DED-665208BB8817Q35178801-560CC8A4-AE9C-4C22-BBE6-C30A2398FABAQ35179957-7D091A27-627B-4BFC-B38A-71FEDE01D6DDQ35357443-11C02902-B969-468E-A921-C67DA3E5ACEE
P2860
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.
@ast
Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.
@en
Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.
@nl
type
label
Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.
@ast
Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.
@en
Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.
@nl
prefLabel
Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.
@ast
Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.
@en
Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.
@nl
P2093
P356
P1433
P1476
Oral treatment with alpha-lipo ...... neuropathy: the SYDNEY 2 trial
@en
P2093
Alexey Barinov
Dan Ziegler
Irina Gurieva
Itamar Raz
Joachim Maus
Maria Novosadova
Peter J Dyck
Phillip A Low
Rustem Samigullin
Ullrich Munzel
P304
P356
10.2337/DC06-1216
P407
P577
2006-11-01T00:00:00Z